|
| Press Releases |
|
 |
|
| Monday, October 21, 2024 |
|
|
Everest Medicines Announces Taiwan TFDA Approval of NEFECON for the Treatment of Primary IgA Nephropathy |
| Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announces that the Taiwan Food and Drug Administration (TFDA) has approved NEFECON indicated "to reduce the loss of kidney function in adult patients with primary immunoglobulin A nephropathy (IgAN) who are at risk for disease progression1". There are no restrictions on initial proteinuria levels in the approved indication. more info >> |
|
| Friday, October 18, 2024 |
|
|
Everest Medicines' Stock Price Rises by 20% as Profit Potential Drives Valuation Recovery |
| Everest Medicines (1952.HK) closed today with a 20.46% increase, hitting a high of HKD 28.6. The company's stock price has been steadily rising since the release of its interim results, with today's trading volume reaching HKD 291 million. Market updates show that BOCOM International released a report assigning an 'outperform' rating to the Chinese pharmaceutical sector, with Everest Medicines being one of the key recommended stocks. more info >> |
|
| Wednesday, October 2, 2024 |
|
|
NEFECON Included in 2024 KDIGO Clinical Practice Guidelines |
| Recently, Everest Medicines has announced another positive development. The company's lead product, NEFECON, as the only in-disease IgA nephropathy (IgAN) treatment, has been included in the "KDIGO 2024 Clinical Practice Guideline for the Management Of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV) (Public Review Draft)" (hereinafter referred to as the "New Guidelines (Draft)"), recommending treatment with a 9-month course of NEFECON for patients who are at risk of progressive kidney function loss with IgAN (2B). more info >> |
|
| Thursday, August 22, 2024 |
|
|
Everest Medicines Announces the Initiation of an Investigator-Initiated Clinical Trial (IIT) |
| Everest Medicines (HKEX 1952.HK, 'Everest', or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced the launch of an Investigator-Initiated Clinical Trial (IIT) for a personalized mRNA cancer vaccine, EVM16, under the study EVM16CX01, at the Peking University Cancer Hospital and Fudan University's Cancer Hospital. more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
Davos Highlights Physical AI as Key Trend, 51 WORLD (6651.HK) Emerges as Industry Implementer
Jan 22, 2026 20:13 HKT/SGT
|
|
|
Open World Launches Saudi Arabia's First RWA Tokenization Center of Excellence to Advance Vision 2030 Digital Economy Goals
Jan 22, 2026 20:00 HKT/SGT
|
|
|
The 35th Education & Careers Expo opens today
Jan 22, 2026 18:00 HKT/SGT
|
|
|
Fujitsu and Mizuho Bank partner to develop new order and payment processing service for SMEs
Jan 22, 2026 11:30 JST
|
|
|
AmplifiX Releases Comprehensive Sector Report on the Rapid Acceleration of Real-World Asset (RWA) Tokenization
Jan 21, 2026 23:00 HKT/SGT
|
|
|
TANAKA PRECIOUS METAL TECHNOLOGIES to Exhibit Advanced Precious Metal Materials for Medical Device Components at MD&M West 2026
Jan 21, 2026 22:00 JST
|
|
|
Honda to Discontinue Production of Fuel Cell Systems at Fuel Cell System Manufacturing LLC in the U.S.
Jan 21, 2026 17:44 JST
|
|
|
Notice regarding the dissolution of the joint venture in the home elevator business
Jan 21, 2026 17:04 JST
|
|
|
Eisai Listed as a Global 100 Most Sustainable Corporation for the Tenth Time
Jan 21, 2026 16:44 JST
|
|
|
MHI and ITB Deepen Research Collaboration on Ammonia-Based Clean Power in Indonesia
Jan 21, 2026 16:37 JST
|
|
|
Asian Financial Forum opens next Monday with a fresh perspective and new tagline, Finance Empowering Business
Jan 21, 2026 14:30 JST
|
|
|
Exito Drives India's Digital-First Revolution with the Flagship 43rd Digital Transformation Summit - India 2026
Jan 21, 2026 13:00 HKT/SGT
|
|
|
MHI-TC Delivers Self-Propelled Mobile Seaport Passenger Boarding Bridge to Yokohama City, Entering Service on January 13th
Jan 21, 2026 11:02 JST
|
|
|
Dowway Proposes Rebranding with a New Name 'Defeng Solife'
Jan 21, 2026 09:51 HKT/SGT
|
|
|
From Computing Chips to Physical AI: Nobel Laureate Hassabis' Trillion-Dollar Paradigm Forecast and 51WORLD's (6651.HK) Industry Breakthrough
Jan 21, 2026 10:00 JST
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
